Sonabend Adam M, Rolle Cleo E, Lesniak Maciej S
Brain Tumor Center, Section of Neurosurgery, The University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA.
Anticancer Res. 2008 Mar-Apr;28(2B):1143-50.
The aggressive nature of gliomas is closely related to their capacity to evade the anti-tumoral immune response. The mechanisms implicated in this phenomenon are only partially understood. A subset of T cells, termed CD4+ CD25+ regulatory T cells (Treg), have been shown to inhibit the actions of effector lymphocytes. These Tregs are increased in the blood and tumors of glioma patients and animals with experimental brain tumors. Moreover, tumor infiltration by Tregs correlates with tumor grade and in animal models, depletion of Tregs is associated with prolonged survival. This review focuses on the role of Tregs in the immune suppression exhibited by malignant gliomas. The biology of these cells is briefly described in this context and finally, potential therapeutic strategies related to Treg ablation are explored.
胶质瘤的侵袭性与其逃避抗肿瘤免疫反应的能力密切相关。这一现象背后的机制仅得到部分理解。一类被称为CD4+ CD25+调节性T细胞（Treg）的T细胞亚群已被证明可抑制效应淋巴细胞的作用。在胶质瘤患者以及患有实验性脑肿瘤的动物的血液和肿瘤中，这些Tregs数量增加。此外，Tregs的肿瘤浸润与肿瘤分级相关，并且在动物模型中，Tregs的清除与生存期延长有关。本综述聚焦于Tregs在恶性胶质瘤所表现出的免疫抑制中的作用。在此背景下简要描述了这些细胞的生物学特性，最后探讨了与Treg消融相关的潜在治疗策略。
